Roivant Sciences (FRA:87S) ROCE %: -27.21% (As of Mar. 2026)


FRA:87S Roivant Sciences Ltd FRA:87S
55 GF Score
Price €30.01
GF Value €9.22
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences ROCE %?

Roivant Sciences FRA:87S +6.91% 55 ROCE % is -27.21% as of Mar. 2026. GuruFocus rates FRA:87S with a GF Score™ of 55/100 and a GF Value™ of €9.22 (Significantly Overvalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Roivant Sciences's annualized ROCE % for the quarter that ended in Mar. 2026 was -27.21%.

Roivant Sciences  (FRA:87S) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Roivant Sciences ROCE % Related Terms

Roivant Sciences ROCE % Historical Data

* Premium members only.

The historical data trend for Roivant Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences ROCE % Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial -39.91 -36.35 -18.12 -18.25 -23.20

Roivant Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.50 -21.58 -24.66 -27.16 -27.21
FRA:87S
55GF Score
Roivant Sciences Ltd FRA:87S
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roivant Sciences ROCE % Calculation

Roivant Sciences's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=-1111.787/( ( (5029.169 - 138.205) + (4938.014 - 243.276) )/ 2 )
=-1111.787/( (4890.964+4694.738)/ 2 )
=-1111.787/4792.851
=-23.20 %

Roivant Sciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-1228.284/( ( (4462.464 - 129.777) + (4938.014 - 243.276) )/ 2 )
=-1228.284/( ( 4332.687 + 4694.738 )/ 2 )
=-1228.284/4513.7125
=-27.21 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -27.21% mean?
Roivant Sciences (FRA:87S) has a ROCE % of -27.21% as of Mar. 2026.
Is Roivant Sciences' ROCE % too high?
Roivant Sciences' current ROCE % is -27.21%. Overall, Roivant Sciences has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' ROCE % compare to INSM and INCY?
Roivant Sciences' ROCE % of -27.21% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Roivant Sciences's current ROCE % is -27.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (FRA:87S) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.22, compared to a current price of €30.01 — trading 225.5% above its estimated fair value. The current ROCE % is -27.21%. Roivant Sciences' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Roivant Sciences (FRA:87S), the current ROCE % is -27.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roivant Sciences (FRA:87S) Overvalued in 2026?

Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued. The current stock price of €30.01 is trading 225.5% above its estimated GF Value™ of €9.22. GuruFocus considers Roivant Sciences to be Significantly Overvalued.

Key valuation signals for FRA:87S:

  • ROCE %: -27.21%
  • GF Value™: €9.22 vs. price of €30.01 (225.5% above fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the FRA:87S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roivant Sciences Business Description

Other Exchanges ROIV:USA87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score

Get the complete analysis for FRA:87S

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.01
Price
€9.22
GF Value